Tumour necrosis factor inhibitor-related lupus: Safety of switching agents

Clinical Rheumatology

Volumn 29, Issue 5, 2010, Pages 551-553

  Luong, Jessica M T ^a   Tan, Boon T ^b   Buchanan, Russell R C ^a   Schachna, Lionel ^a  

^a AUSTIN HEALTH   (Australia)

^b NORTHERN HOSPITAL   (Australia)

Author keywords

Ankylosing spondylitis; Lupus; Switching; TNF inhibitors

Indexed keywords

ANTINUCLEAR ANTIBODY; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; DOUBLE STRANDED DNA ANTIBODY; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ANKYLOSING SPONDYLITIS; ANTIBODY TITER; ARTHRALGIA; ARTICLE; BACKACHE; CASE REPORT; COLD INJURY; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; JOINT LIMITATION; PAPULAR RASH; PRIORITY JOURNAL; RAYNAUD PHENOMENON; RECURRENT DISEASE; SPINE MOBILITY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; AUTOIMMUNITY; DNA; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFLAMMATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; QUALITY OF LIFE; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLITIS, ANKYLOSING; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77950862020     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-009-1365-y     Document Type: Article

References (10)

1. Drug-induced lupus erythematosus: an emerging association with TNF inhibitors. Australian Adverse Drug Reactions Bulletin 2009;28:10-11
2. M De Bandt J Sibilia X Le Loet, et al. 2005 Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey Arthritis Res Ther 7 R545 R551 10.1186/ar1715 15899041
3. M Ramos-Casals P Brito-Zeron S Munoz, et al. 2007 Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases Medicine (Baltimore) 86 242 251 10.1097/MD.0b013e3181441a68 (Pubitemid 47067483)
4. MF Costa NR Said B Zimmermann 2008 Drug-induced lupus due to anti-tumor necrosis factor alpha agents Semin Arthritis Rheum 37 381 387 10.1016/j.semarthrit.2007.08.003 1:CAS:528:DC%2BD1cXmsFKqsb0%3D 17977585 (Pubitemid 351734520)
5. EL Williams S Gadola CJ Edwards 2009 Anti-TNF-induced lupus Rheumatology 48 716 720 10.1093/rheumatology/kep080 1:CAS:528:DC%2BD1MXnslKhurc%3D 19416947
6. T Bongartz AJ Sutton MJ Sweeting I Buchan EL Matteson V Montori 2006 Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials JAMA 295 2275 2285 10.1001/jama.295.19. 2275 1:CAS:528:DC%2BD28Xksl2ktrk%3D 16705109 (Pubitemid 43736578)
7. J Thornhill KD Watson PA Lord P Symmons KL Hyrich 2008 Drug-induced lupus in patients with inflammatory arthritis treated with TNF blocking agents: results from the BSR biologics register Rheumatology 47 ii15
8. M Siegel SL Lee NS Peress 1967 The epidemiology of drug-induced systemic lupus erythematosus Arthritis Rheum 10 407 415 10.1002/art.1780100502 1:STN:280:DyaF1c%2FksFOhug%3D%3D 6057644
9. T Matsuura Y Shimizu H Fujimoto T Miyazaki S Kano 1992 Minocycline-related lupus Lancet 340 1553 10.1016/0140-6736(92)92810-3 1:STN:280:DyaK3s7gvV2ltw%3D%3D 1361646
10. L Kocharla AB Mongey 2009 Is the development of drug-related lupus a contraindication for switching from one TNF alpha inhibitor to another? Lupus 18 169 171 10.1177/0961203308093922 1:STN:280:DC%2BD1M%2FotFSrtg%3D%3D 19151120